Santral Seröz Korioretinopati
Özet
Santral Seröz Korioretinopati (SSKR), maküla ve çevresinde retina pigment epiteli (RPE) ile diğer katmanlar arasında sıvı birikimi ve seröz dekolmanla karakterize, etiyolojisi kesin bilinmeyen bir göz hastalığıdır. Genellikle tedavi gerektirmeden kendiliğinden gerileyen bu rahatsızlık, çoğunlukla 40-45 yaş aralığındaki genç ve orta yaşlı erkeklerde görme azlığı ve şekil bozukluğu (metamorfopsi) ile ortaya çıkar. En önemli risk faktörleri arasında yoğun stres, Tip A kişilik yapısı, artmış serum kortizol düzeyi ve dışarıdan steroid (glukokortikoid) kullanımı yer almaktadır. Ayrıca gebelik, sigara-alkol tüketimi ve hipertansiyon da riski artırır. Hastalığın patogenezinde koroidal vasküler geçirgenliğin artması ve kan-retina bariyerinin bozulması temel rol oynar. Tanıda Optik Koherens Tomografi (OCT), Fundus Fluoresein Anjiografi (FFA) ve İndosiyanin Yeşili Anjiografisi (İCGA) gibi ileri görüntüleme yöntemleri kullanılır; özellikle invaziv olmayan OCT en yaygın tercih edilen seçenektir. Vakaların büyük kısmı 6-8 haftada konservatif yaklaşımlarla (stresten kaçınma, sigara/alkolü azaltma) iyileşse de, 6 aydan uzun süren kronik durumlarda kalıcı görme kaybı riski ve Koroidal Neovasküler Membran (KNVM) gelişimi görülebilir. Kronik ve dirençli olgularda Asetozolamid gibi medikal tedaviler ile düşük doz verteporfin içeren Fotodinamik Tedavi (FDT) en etkin seçenekler olarak öne çıkmaktadır.
Central Serous Chorioretinopathy (CSCR) is an eye disease of uncertain etiology characterized by fluid accumulation and serous detachment between the retinal pigment epithelium (RPE) and other retinal layers in the macula or peripheral areas. Typically regressing spontaneously without treatment, this condition predominantly manifests as visual loss and metamorphopsia in young and middle-aged male patients, most frequently between the ages of 40 and 45. The primary risk factors include intense stress, Type A personality, elevated serum cortisol levels, and exogenous glucocorticoid therapy, while pregnancy, smoking, alcohol consumption, and hypertension also elevate the risk. The underlying pathogenesis involves increased choroidal vascular permeability and the disruption of the blood-retinal barrier. Advanced imaging modalities such as Optical Coherence Tomography (OCT), Fundus Fluorescein Angiography (FFA), and Indocyanine Green Angiography (ICGA) are utilized for diagnosis, with non-invasive OCT being the most widely preferred method. Although the majority of acute cases resolve within 6 to 8 weeks through conservative management like stress reduction and lifestyle modifications, chronic cases lasting longer than 6 months carry a risk of permanent visual impairment and the development of Choroidal Neovascular Membrane (CNVM). For chronic and refractory patients, medical interventions like Acetazolamide and low-dose verteporfin Photodynamic Therapy (PDT) emerge as the most effective management strategies.
Referanslar
Graefe, A. V. (1866). Über die zentrale rezidivierende Retinitis. Graefes Arch Ophthalmol, 12, 211-215.
Gass, J. Donald M. "Bullous retinal detachment: an unusual manifestation of idiopathic central serous choroidopathy." American journal of ophthalmology 75.5 (1973): 810-821.
Gilbert, C. M., Owens, S. L., Smith, P. D., & Fine, S. L. (1984). Long-term follow-up of central serous chorioretinopathy. British Journal of Ophthalmology, 68(11), 815-820.
Klein, M. L., Van Buskirk, E. M., Friedman, E., Gragoudas, E., & Chandra, S. (1974). Experience with nontreatment of central serous choroidopathy. Archives of Ophthalmology, 91(4), 247-250.
Jain, I. S., & Singh, K. (1966). Maculopathy a corticosteroid side-effect. Indian Journal of Ophthalmology, 14(6), 250.
Gass, J. D. M. (1991). Central serous chorioretinopathy and white subretinal exudation during pregnancy. Archives of ophthalmology, 109(5), 677-681.
Eckstein, M. B., Spalton, D. J., & Holder, G. (1993). Visual loss from central serous retinopathy in systemic lupus erythematosus. The British journal of ophthalmology, 77(9), 607.
Yoshioka, H. (1991). The etiology of central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi, 95(12), 1181-1195.
Yap, E. Y., & Robertson, D. M. (1996). The long-term outcome of central serous chorioretinopathy. Archives of Ophthalmology, 114(6), 689-692.
Yu, H., Xia, G. Y., Gao, M. H., Yu, J., & Zhang, Y. Y. (2011). Morphologic changes in acute central serous chorioretinopathy evaluated by spectral domain optical coherence tomography. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 47(6), 508-515.
Inoue, R., Sawa, M., Tsujikawa, M., & Gomi, F. (2010). Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. American journal of ophthalmology, 149(3), 441-446.
Daruich, A., Matet, A., Dirani, A., Bousquet, E., Zhao, M., Farman, N., ... & Behar-Cohen, F. (2015). Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Progress in retinal and eye research, 48, 82-118.
Nagayoshi, K. (1971). Experimental study of choroidoretinopathy by intravenous injection of adrenaline. Nippon Ganka Gakkai Zasshi, 75(8), 1720-1727.
Guyer, D. R., Yannuzzi, L. A., Slakter, J. S., Sorenson, J. A., Ho, A., & Orlock, D. (1995). Digital indocyanine green videoangiography of central serous chorioretinopathy. Retina, 15(1), 79-80.
Marmor, M. F. (1988). New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefe's archive for clinical and experimental ophthalmology, 226(6), 548-552.
Kim, Y. T., Kang, S. W., & Bai, K. H. (2011). Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye, 25(12), 1635-1640.
Sawa, M., Gomi, F., Harino, S., Ohguro, N., Ohji, M., & Tano, Y. (2005). Three-dimensional optical coherence tomographic findings of idiopathic multiple serous retinal pigment epithelial detachment. Archives of Ophthalmology, 123(1), 122-123.
Chan, W. M., Lam, D. S. C., Lai, T. Y. Y., Tam, B. S. M., Liu, D. T. L., & Chan, C. K. M. (2003). Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. British Journal of Ophthalmology, 87(12), 1453-1458.
Klein, M. L., Van Buskirk, E. M., Friedman, E., Gragoudas, E., & Chandra, S. (1974). Experience with nontreatment of central serous choroidopathy. Archives of Ophthalmology, 91(4), 247-250.
Pikkel, J., Beiran, I., Ophir, A., & Miller, B. (2002). Acetazolamide for central serous retinopathy. Ophthalmology, 109(9), 1723-1725.
Caporossi, T., D'Amico, G., Pagliara, M., Molle, F., Lepore, D., Focosi, F., & Balestrazzi, E. (2010). Low-Fluence Photodynamic Therapy In Longstanding Chronic Central Serous Chorioretinopathy With Foveal and Gravitational Atrophy. Investigative Ophthalmology & Visual Science, 51(13), 1349-1349.
Chatziralli, I., Vlachodimitropoulou, A., Daoula, C., Vrettou, C., Galani, E., Theodossiadis, G., & Theodossiadis, P. (2018). Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. International journal of retina and vitreous, 4(1), 1-5.
Avci, R., & Deutman, A. F. (1993). Die Behandlung der zentralen serösen Choroidopathie mit dem Betarezeptorenblocker Metoprolol (vorläufige Ergebnisse). Klinische Monatsblätter für Augenheilkunde, 202(03), 199-205.
Van Rijssen, T. J., Van Dijk, E. H., Yzer, S., Ohno-Matsui, K., Keunen, J. E., Schlingemann, R. O., ... & Boon, C. J. (2019). Central serous chorioretinopathy: towards an evidence-based treatment guideline. Progress in retinal and eye research, 73, 100770.
Seong, H. K., Bae, J. H., Kim, E. S., Han, J. R., Nam, W. H., & Kim, H. K. (2009). Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica, 223(5), 343-347.
Leaver, P. E. T. E. R., & Williams, C. H. R. I. S. T. I. N. E. (1979). Argon laser photocoagulation in the treatment of central serous retinopathy. British Journal of Ophthalmology, 63(10), 674-677.
Chan, W. M., Lai, T. Y., Lai, R. Y., Liu, D. T., & Lam, D. S. (2008). Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology, 115(10), 1756-1765.
Chan, W. M., Lai, T. Y., Lai, R. Y., Tang, E. W., Liu, D. T., & Lam, D. S. (2008). Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina, 28(1), 85-93.
